{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:53:19Z","timestamp":1791910399501,"version":"4.3.4"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2022\/12925-8"],"award-info":[{"award-number":["2022\/12925-8"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["303116\/2022-6"],"award-info":[{"award-number":["303116\/2022-6"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["318356\/2025-2"],"award-info":[{"award-number":["318356\/2025-2"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["305242\/2019-9"],"award-info":[{"award-number":["305242\/2019-9"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.vaccine.2026.129227","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:38:48Z","timestamp":1791391128000},"page":"129227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Prospective controlled study of the recombinant zoster vaccine in autoimmune rheumatic disease: robust seroconversion despite intravenous cyclophosphamide"],"prefix":"10.1016","volume":"93","author":[{"given":"Nadia E.","family":"Aikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia B.","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra G.","family":"Pasoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana C.","family":"Medeiros-Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana P.C.","family":"Seguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana P.","family":"Luppino-Assad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily F.N.","family":"Yuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lissiane K.N.","family":"Guedes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clovis A.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eloisa","family":"Bonfa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.129227_bb0005","article-title":"Herpes zoster infection","volume":"364","author":"Le","year":"2019","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129227_bb0010","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/hematology.2020000116","article-title":"Practical approach to monitoring and prevention of infectious complications associated with systemic corticosteroids, antimetabolites, cyclosporine, and cyclophosphamide in nonmalignant hematologic diseases","volume":"2020","author":"Malpica","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"11","key":"10.1016\/j.vaccine.2026.129227_bb0015","doi-asserted-by":"crossref","first-page":"5042","DOI":"10.1093\/rheumatology\/keab538","article-title":"Use of disease-modifying antirheumatic drugs and the subsequent risk of herpes zoster in older adults","volume":"60","author":"Qian","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.vaccine.2026.129227_bb0020","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13045-022-01287-3","article-title":"Post-transplant cyclophosphamide alters immune signatures and leads to impaired T cell reconstitution in allogeneic hematopoietic stem cell transplant","volume":"15","author":"Zhao","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.vaccine.2026.129227_bb0025","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00280-016-3152-1","article-title":"The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy","volume":"78","author":"Ahlmann","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129227_bb0030","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129227_bb0035","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2278362","article-title":"Recombinant zoster vaccine in immunocompetent and immunocompromised adults: a review of clinical studies","volume":"19","author":"Mwakingwe-Omari","year":"2023","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"10.1016\/j.vaccine.2026.129227_bb0040","doi-asserted-by":"crossref","first-page":"e363","DOI":"10.1016\/S2665-9913(25)00313-3","article-title":"Recombinant herpes zoster vaccine in patients with autoimmune rheumatic diseases in Brazil: a double-blind, randomised, placebo-controlled, phase 4, non-inferiority study","volume":"8","author":"Aikawa","year":"2026","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.vaccine.2026.129227_bb0045","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1038\/s41591-021-01469-5","article-title":"Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial","volume":"27","author":"Medeiros-Ribeiro","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2026.129227_bb0050","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1136\/ard.2011.150250","article-title":"Immunogenicity and safety of the 2009 non-adjuvanted influenza a\/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases","volume":"70","author":"Saad","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2026.129227_bb0055","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1097\/RHU.0000000000002216","article-title":"Disease safety, immunogenicity, and efficacy of recombinant herpes zoster vaccine (RZV or Shingrix) in autoimmune rheumatic diseases: launching a randomized phase 4 study","volume":"31","author":"Kupa","year":"2025","journal-title":"J Clin Rheumatol"},{"issue":"9","key":"10.1016\/j.vaccine.2026.129227_bb0060","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1002\/art.39670","article-title":"Risk of herpes zoster in autoimmune and inflammatory diseases: implications for vaccination","volume":"68","author":"Yun","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"10.1016\/j.vaccine.2026.129227_bb0065","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/infdis\/jiy095","article-title":"Immune responses to a recombinant glycoprotein E herpes zoster vaccine in adults aged 50 years or older","volume":"217","author":"Cunningham","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129227_bb0070","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.coi.2019.02.009","article-title":"Understanding the immunology of Shingrix, a recombinant glycoprotein E adjuvanted herpes zoster vaccine","volume":"59","author":"Heineman","year":"2019","journal-title":"Curr Opin Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129227_bb0075","doi-asserted-by":"crossref","first-page":"2263979","DOI":"10.1080\/21645515.2023.2263979","article-title":"Effectiveness and safety of recombinant zoster vaccine: a review of real-world evidence","volume":"19","author":"Parikh","year":"2023","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"10.1016\/j.vaccine.2026.129227_bb0080","doi-asserted-by":"crossref","first-page":"e352","DOI":"10.1016\/S2665-9913(24)00084-5","article-title":"Immunogenicity, reactogenicity, and safety of two-dose adjuvanted herpes zoster subunit vaccine in patients with systemic lupus erythematosus in South Korea: a single-centre, randomised, double-blind, placebo-controlled trial","volume":"6","author":"Park","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.vaccine.2026.129227_bb0085","doi-asserted-by":"crossref","DOI":"10.1002\/acr.80103","article-title":"Immunogenicity, safety, and determinants of recombinant zoster vaccine response in idiopathic inflammatory myopathies: a phase 4 randomized trial","author":"Pasoto","year":"2026","journal-title":"Arthritis Care Res"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26010364?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26010364?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:24:04Z","timestamp":1791908644000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26010364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":17,"alternative-id":["S0264410X26010364"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129227","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prospective controlled study of the recombinant zoster vaccine in autoimmune rheumatic disease: robust seroconversion despite intravenous cyclophosphamide","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129227","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"129227"}}